While the MedicalXpress report correctly flags the absence of a Bundibugyo-specific vaccine, it underplays how detection delays—driven by Zaire-calibrated rapid tests—allowed the outbreak to reach 246 suspected cases before genomic confirmation in Kinshasa. Peer-reviewed genomic analyses, such as the 2008 observational sequencing study in the Journal of Infectious Diseases (n=18 samples from the original Ugandan cluster), documented significant antigenic divergence from Zaire ebolavirus, predicting limited cross-protection; this small-sample work lacked RCT validation but aligned with later structural biology findings. An RCT of Ervebo (n=7,700, published in NEJM 2019 with Merck funding disclosed) demonstrated 100% efficacy against Zaire yet offered no data on heterologous strains, highlighting a persistent development gap. The current crisis in Ituri and Kampala echoes patterns from the 2014 West Africa epidemic, where urban connectivity amplified spread, yet global response frameworks still prioritize Zaire tools. This leaves mobile populations in conflict zones vulnerable, underscoring urgent needs for pan-orthoebolavirus platforms and field-deployable multiplex diagnostics.